You're right, Zeppo, in retrospect that should have been a gamechanger. But it wasn't so simple -
From what I learned, the CEO of Belleville didn't allow further testing or promotion of AS because it would have constituted a conflict of interest for Dr. Zoutman, who was a Department Head there.
Besides that, the goal always was the US market, so finding ways to push for more exposure in Canada may have seemed to be an unnecessary distraction.
Then came the interminable delays in the EPA process, to be followed by the FDA'a reversal of its position.
By that time I can imagine that they looked back in remorse that the Belleville success hadn't been exploited more.
Just one of many, many, "what-ifs" and strategic blunders that led us to where we are today: engaging in our own "what-ifs" and remorse.
